
Myomo (MYO) Stock Forecast & Price Target
Myomo (MYO) Analyst Ratings
Bulls say
Myomo's reimbursement pipeline demonstrated consistent growth, increasing from 1,389 units in Q4 to 1,669 units in the current quarter, indicating a positive trend in the company's ability to secure reimbursements for its innovative myoelectric orthosis products. The company has strategically redirected its focus toward the large Medicare market, which comprises approximately 22% of its projected revenue in 2024, positioning itself for substantial growth. Furthermore, a recent positive ruling from the Centers for Medicare & Medicaid Services to include the MyoPro device in Medicare Part B benefits significantly expands its potential market, underscoring the increasing acceptance and demand for Myomo's technology.
Bears say
Myomo Inc. has lowered its 2025 revenue guidance to $40 – 42 million, a significant decrease from the previous estimate of $50 – 53 million, indicating a more pessimistic outlook for financial performance. Additionally, the company is experiencing a decline in its backlog of insurance-authorized orders, which decreased from 272 in Q4 to 208, suggesting challenges in demand and pipeline conversion. Furthermore, recent marketing efforts and pipeline quality have failed to meet expectations, further exacerbating concerns about lead generation and overall growth potential.
This aggregate rating is based on analysts' research of Myomo and is not a guaranteed prediction by Public.com or investment advice.
Myomo (MYO) Analyst Forecast & Price Prediction
Start investing in Myomo (MYO)
Order type
Buy in
Order amount
Est. shares
0 shares